Anna D. Garrett, PharmD, BCPS, CPP
Published Online: Friday, June 1, 2007

A recent Euro-pean study examined the contribution of the metabolic syndrome to the risk of developing venous throm-boembolism (VTE). This case?control study was designed to investigate the presence of the metabolic syndrome, defined according to guidelines of the National Cholesterol Education Program, in high-risk patients with objectively confirmed recurrent VTE who had had at least 1 unprovoked event of deep vein thrombosis or pulmonary embolism. A total of 116 VTE patients and 129 controls were enrolled. The prevalence of the metabolic syndrome was statistically significantly higher in VTE patients (40/116; 35%) than in controls (26/129; 20%; P = .012). The adjusted odds ratio of the metabolic syndrome for VTE was 2.2 after adjustment for established thrombosis risk factors, sex, and age. Individuals with the metabolic syndrome (n = 66) had significantly higher levels of high-sensitivity C-reactive protein, fibrinogen, and factor VIII activity, compared with patients without metabolic syndrome.

Latest Articles
Pharmacies are rated as some of the best places to receive top-notch customer service in America.
Often caused by acid reflux, eosinophilic esophagitis is an emerging inflammatory disease that is generally unresponsive to proton pump inhibitor therapy.
Carlos Aquino, founder and president of PharmaDiversion LLC, discusses timing of inspections from the Drug Enforcement Administration.
The FDA has again rejected AMAG Pharmaceuticals’ application for a single-dose version of hydroxyprogesterone caproate injection (Makena) to reduce the risk of preterm birth for at-risk women.
Latest Issues